Inside Nephrology: A Weekly Review
Nefrologia
Nephrology Updates: CKD Management and Therapeutic Advances
This week's nephrology update covers dapagliflozin's effects on bone biomarkers, finerenone combination therapies, hypoparathyroidism treatment advances, and innovative approaches to CKD management.
Accedi o Registrati per ascoltare questo episodio
Bibliografia
1. Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis.
Authors: Pelepenko LE, Barreto J, Martins MP, et al.
Journal: Calcified tissue international, 2026 Aug 14
PMID: 42595915
DOI: 10.1007/s00223-026-01587-7
2. Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.
Authors: Agarwal R, Correa-Rotter R, Navaneethan SD, et al.
Journal: Hypertension (Dallas, Tex. : 1979), 2026 Sep
PMID: 42244376
DOI: 10.1161/HYPERTENSIONAHA.126.27036
3. Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real-world observational study.
Authors: Zhao X, Liu B, Sun R, et al.
Journal: Journal of diabetes investigation, 2026 Sep
PMID: 42332386
DOI: 10.1111/jdi.70368
4. Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.
Authors: Ono T, Okada T, Takahashi N, et al.
Journal: Blood advances, 2026 Aug 25
PMID: 42275565
DOI: 10.1182/bloodadvances.2026019701
5. Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial.
Authors: Rejnmark L, Gosmanova EO, Khan AA, et al.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2026 Aug 21
PMID: 42166177
DOI: 10.1093/jbmr/zjag085
6. Obesity management for kidney TRANSPLANTation: protocol for the vanguard phase of an innovative randomised controlled trial, embedded in routine care (OK-TRANSPLANT 2).
Authors: Clemens KK, Irwin J, Chiu M, et al.
Journal: BMJ open, 2026 Aug 11
PMID: 42580835
DOI: 10.1136/bmjopen-2026-120427
7. Anthropometric characteristics at birth and growth outcome in patients with X-linked hypophosphatemia treated with oral phosphate and active vitamin D.
Authors: Przygodda S, Brieger LC, Bohlen AV, et al.
Journal: Pediatric nephrology (Berlin, Germany), 2026 Sep
PMID: 41963716
DOI: 10.1007/s00467-026-07271-0
8. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study.
Authors: Takeuchi T, van Vollenhoven R, Ueki Y, et al.
Journal: Modern rheumatology, 2026 Aug 31
PMID: 41967478
DOI: 10.1093/mr/roag031
9. Kidney outcomes of coenzyme Q10 supplementation in patients with genetically confirmed CoQ10 nephropathy in Japan.
Authors: Nagano C, Ushijima K, Tezuka Y, et al.
Journal: Clinical and experimental nephrology, 2026 Sep
PMID: 42435122
DOI: 10.1007/s10157-026-02917-7
10. Feasibility, safety and tolerability of intradialytic creatine supplementation in hemodialysis: A double-blind, randomized, placebo-controlled pilot study.
Authors: Doorenbos CSE, van der Veen Y, Post A, et al.
Journal: PloS one, 2026
PMID: 42555603
DOI: 10.1371/journal.pone.0354883
Authors: Pelepenko LE, Barreto J, Martins MP, et al.
Journal: Calcified tissue international, 2026 Aug 14
PMID: 42595915
DOI: 10.1007/s00223-026-01587-7
2. Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.
Authors: Agarwal R, Correa-Rotter R, Navaneethan SD, et al.
Journal: Hypertension (Dallas, Tex. : 1979), 2026 Sep
PMID: 42244376
DOI: 10.1161/HYPERTENSIONAHA.126.27036
3. Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real-world observational study.
Authors: Zhao X, Liu B, Sun R, et al.
Journal: Journal of diabetes investigation, 2026 Sep
PMID: 42332386
DOI: 10.1111/jdi.70368
4. Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.
Authors: Ono T, Okada T, Takahashi N, et al.
Journal: Blood advances, 2026 Aug 25
PMID: 42275565
DOI: 10.1182/bloodadvances.2026019701
5. Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial.
Authors: Rejnmark L, Gosmanova EO, Khan AA, et al.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2026 Aug 21
PMID: 42166177
DOI: 10.1093/jbmr/zjag085
6. Obesity management for kidney TRANSPLANTation: protocol for the vanguard phase of an innovative randomised controlled trial, embedded in routine care (OK-TRANSPLANT 2).
Authors: Clemens KK, Irwin J, Chiu M, et al.
Journal: BMJ open, 2026 Aug 11
PMID: 42580835
DOI: 10.1136/bmjopen-2026-120427
7. Anthropometric characteristics at birth and growth outcome in patients with X-linked hypophosphatemia treated with oral phosphate and active vitamin D.
Authors: Przygodda S, Brieger LC, Bohlen AV, et al.
Journal: Pediatric nephrology (Berlin, Germany), 2026 Sep
PMID: 41963716
DOI: 10.1007/s00467-026-07271-0
8. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study.
Authors: Takeuchi T, van Vollenhoven R, Ueki Y, et al.
Journal: Modern rheumatology, 2026 Aug 31
PMID: 41967478
DOI: 10.1093/mr/roag031
9. Kidney outcomes of coenzyme Q10 supplementation in patients with genetically confirmed CoQ10 nephropathy in Japan.
Authors: Nagano C, Ushijima K, Tezuka Y, et al.
Journal: Clinical and experimental nephrology, 2026 Sep
PMID: 42435122
DOI: 10.1007/s10157-026-02917-7
10. Feasibility, safety and tolerability of intradialytic creatine supplementation in hemodialysis: A double-blind, randomized, placebo-controlled pilot study.
Authors: Doorenbos CSE, van der Veen Y, Post A, et al.
Journal: PloS one, 2026
PMID: 42555603
DOI: 10.1371/journal.pone.0354883
